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OBJECTIVES: Biological markers that predict the development of invasive breast cancer are needed to improve
personalized therapy for patients diagnosed with ductal carcinoma in situ. We investigated the role of basal
cytokeratin 5/6 in the risk of invasion in breast ductal carcinoma in situ.
METHODS: We constructed tissue microarrays using 236 ductal carcinoma in situ samples: 90 pure samples
(group 1) and 146 samples associated with invasive carcinoma (group 2). Both groups had similar nuclear grades
and were obtained from patients of similar ages. The groups were compared in terms of estrogen (ER) and
progesterone receptor (PR) status, human epidermal growth factor receptor 2 (HER2) expression, cytokeratin
5/6 immunostaining, human epidermal growth factor receptor 1 (EGFR) membrane staining and molecular
subtype, as indicated by their immunohistochemistry profiles.
RESULTS: ER/PR-negative status was predictive of invasion, whereas HER2 superexpression and cytokeratin 5/6-
positive status were negatively associated with invasion. Among the high-grade ductal carcinoma in situ cases,
a triple-positive profile (positive for estrogen receptor, progesterone receptor, and HER2) and cytokeratin 5/6
expression by neoplastic cells were negatively associated with invasion. In the low-grade ductal carcinoma in
situ subgroup, only cytokeratin 5/6 expression exhibited a negative association with the probability of
invasion.
CONCLUSION: The immunohistochemical expression of cytokeratin 5/6 by ductal carcinoma in situ epithelial
cells may provide clinically useful information regarding the risk of progression to invasive disease.
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& INTRODUCTION
Ductal carcinoma in situ (DCIS) consists of a group
of precursor lesions of invasive breast cancer (1). The
prevalence of DCIS has been increasing over the last several
decades, which is likely due to improvements in screening
programs; DCIS now accounts for approximately 20–25%
of all breast cancer diagnoses (2). Experience with this
increasing number of DCIS diagnoses has revealed the
heterogeneity of this group, particularly in terms of the risk
of associated invasive disease and risk of recurrence, with
most recurrences appearing as invasive cancer (3–5).
Although wide surgical margins substantially reduce the
risk of recurrence, the safe omission of radiotherapy in
certain patient subgroups has not yet been incorporated into
practical clinical use (6,7). The appropriate criteria for
sentinel lymph node biopsy in DCIS, which are based on
the risk of discovering invasive disease according to the
final pathology report, are another source of controversy.
Although a consensus is lacking, young age, the presence of
palpable tumors, lesion size and histological grade are used
as guidelines for sentinel lymph node biopsy (8). There is a
recognized need for individualized treatment of all patients
with breast cancer, including those with preinvasive lesions,
who would particularly benefit from the discovery of
markers of invasive risk.
The expression of basal cytokeratins (CKs) determined
using immunohistochemistry, together with human epider-
mal growth factor receptor 1 (EGFR or HER1) expression,
defines the basal-like subgroup of triple-negative (TN)
invasive ductal carcinomas (9), which are correlated with
a poor prognosis (10,11). The same invasive carcinoma
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molecular profiles have been identified in DCIS cases, albeit
with a lower incidence of the basal-like phenotype (12).
Although the expression of certain basal CKs, such as CK 5/
6 and EGFR, has been used to define the molecular basal-
like subtype of DCIS, CK 5/6 has not been explored as an
independent indicator of biological behavior, particularly
the risk of invasion. In this study, we compared the
immunoexpression of basal CK 5/6 and other classic
prognostic histological variables in DCIS samples with
and without invasive components.
& MATERIALS AND METHODS
Patient selection and clinicopathological
parameters
This retrospective study was approved by the Scientific
Committee of the Department of Pathology of the Faculdade
de Medicina da Universidade de Sa˜o Paulo and by the
Ethics Committee for Research Projects of the Hospital das
Clı´nicas da Faculdade de Medicina da Universidade de Sa˜o
Paulo (CAPPesq, process 2011/14741-7). Because the study
was retrospective, informed patient consent was waived,
and all patient identifiers were removed. Breast samples
with confirmed diagnoses of DCIS of the breast, with and
without an invasive carcinoma (IC) component, were
obtained from the files of the Division of Surgical
Pathology of the Faculdade de Medicina da Universidade
de Sa˜o Paulo between 2000 and 2009. All of the tissues had
been fixed in 10% buffered formaldehyde and were
embedded in paraffin. The slides were rigorously reviewed
and classified by a single pathologist (FNA) with expertise
in breast pathology. For cases with interpretations that
differed from the original reports, a consensus was reached
(by FNA and FMC) by a simultaneous examination under a
dual-head microscope. Nuclear grades 1 and 2 were
grouped into the low-grade category, and nuclear grade 3
was defined as the high-grade category. We selected
representative areas of DCIS and invasive components for
tissue microarray (TMA) construction and immunohisto-
chemical analysis. Samples with nonductal histology,
insufficient material for immunohistochemical evaluation
or signs of tissue autolysis, as well as those from pregnant
patients, were excluded from the study. We obtained 236
samples; 90 (38.1%) represented cases of DCIS not asso-
ciated with invasive carcinoma, and 146 (61.9%) represented
cases of DCIS associated with invasive carcinoma.
Tissue microarray construction
The TMA was constructed at the Laboratory of Medical
Investigation (LIM-14) of the Faculdade de Medicina da
Universidade de Sa˜o Paulo. Representative areas were
identified on hematoxylin- and eosin-stained slides and
were marked on paraffin blocks. Cylindrical tissues 2.0 mm
in diameter were punched from regions of DCIS and IC (at
least one sample from each case) in the donor paraffin block
and were mounted onto the recipient block with 1.0-mm
intervals between the cores using a precision microarray
instrument (Beecher Instruments, Silver Spring, MD, USA)
positioned on a fixed sideboard. The cores were organized
in rows and columns, with renal tissue placed in position 1A
for orientation. After the final configuration of the recipient
blocks, the cores were heated to 60 C˚ for 10 minutes and
were sealed for sectioning with the Paraffin Tape-Transfer
System (Instrumedics, St. Louis, MO, USA). We used
silanized slides (StarFrostH) and a microtome for sectioning
at 3-mm intervals (Leica Instruments, Wetzlar, Germany).
The first histological sections were stained with hematox-
ylin-eosin to identify the eventual losses of tissue.
Immunohistochemistry
The immunohistochemical detection of estrogen receptors
(ER), progesterone receptors (PR), HER2 protein, basal CK
5/6 and EGFR was performed on the slides from the TMA
blocks. We applied the following antibodies and dilutions:
SP1 1:500 (Thermo Scientific, Waltharm, MA, USA), PgR636
1:1000 (Dako, Carpeteria, CA, USA), SP3 1:100 (Thermo
Scientific), D5/16B4 1:100 (Dako) and 31G7 1:200 (Zymed,
San Francisco, CA, USA). The appropriate epitope retrieval
method for each specific antibody was used (a pressure
cooker for ER, PR and HER2; a microwave oven for CK 5/6;
and 0.1% pronase for EGFR). Bound antibodies were
detected using NovolinkH (Leica, Bannockburn, IL, USA).
Nuclear positivity was assessed for ER and PR, membra-
nous positivity for HER2 and EGFR and membranous-
cytoplasmic positivity for CK 5/6. Tumors with staining in
at least 1% of the cells were considered positive for ER, PR
or CK 5/6 expression. We employed external positive and
negative controls, as well as internal positive controls. We
considered samples positive for HER2 and EGFR only if
they scored 3+ according to the guidelines of the American
Society of Clinical Oncology (ASCO) and the College of
American Pathologists (CAP) (13).
The DCIS samples were classified into molecular sub-
types according to the following surrogate criteria: luminal
A samples exhibited HER2-negative lesions with at least
50% ER- and/or PR-positive neoplastic cells; luminal B
samples exhibited HER2-negative lesions with less than 50%
ER- and/or RP-positive cells; triple-positive samples were
HER2-positive and ER- and/or PR-positive; HER2-enriched
samples were HER2-positive and ER- and/or PR-negative;
and TN samples were ER-, PR- and HER2-negative. The
luminal A and B subtypes were later combined into a single
category, ‘‘luminal’’, because only three cases expressed less
than 50% of the evaluated hormonal receptors.
Statistical analysis
A t-test was used to compare the ages of the patients in
group 1 (DCIS without invasion) and group 2 (DCIS with
invasion) after the normal distribution of the data was
confirmed using the Kolmogorov-Smirnov test. A chi-
square test was used to evaluate the relationship between
the presence of invasion and the categorical variables (i.e.,
nuclear grade, ER/RP status, HER2 expression, molecular
profile, CK 5/6 expression and EGFR expression). Odds
ratios (ORs) with 95% confidence intervals (CIs) were
calculated for these variables. For the multivariate analysis,
the variables that were significant in the univariate evalua-
tion were analyzed with logistic regression using the
stepwise method. The statistical analyses were performed
using MedCalc software for Windows (version 11.5.0.0;
MedCalc Software, Mariakerke, Belgium), and p-values
smaller than 0.05 were considered significant.
& RESULTS
The distributions of age and the morphological and
immunohistochemical characteristics of group 1 (DCIS
without invasion) and group 2 (DCIS with IBC) are
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summarized in Table 1. There were no significant differ-
ences regarding age, nuclear grade or EGFR expression
between the two groups. A larger number of TN cases were
identified in group 2 (14.4%) compared with group 1 (4.4%)
(p= 0.01). In contrast, group 1 exhibited more ER/PR-
positive lesions (84.4% vs. 71.2%, p= 0.03) and more cases
with CK 5/6 expression (30.6% vs. 11.3%; p= 0.0007).
According to the multivariate analysis, ER/PR-negative
status (p= 0.001) was a predictor of associated invasive
carcinoma, whereas HER2-positive status (p= 0.33) and CK
5/6-positive status were negatively associated with the
presence of invasion (p= 0.0001) (Table 2).
The pathological characteristics of high-grade DCIS are
described in Table 3. The presence of invasion was
associated with negative ER, PR and HER2 expression.
The TN phenotype was more common in group 2 (35.3% vs.
14.8%), but the most striking difference in molecular profiles
was the lower frequency of triple-positive cases observed in
group 2 (3.9% vs. 33.3%) (p= 0.003). Although CK 5/6
expression (Figure 1) was lower in group 2 than in group 1
(17% vs. 34.6%) (p= 0.09), this difference did not reach
statistical significance.
The characteristics of low-grade DCIS are presented in
Table 4. In this subgroup, CK 5/6 expression was the only
characteristic that differed between the cases with and
without invasion (8.1% and 28.8%, respectively, p= 0.002)
(Figure 1).
& DISCUSSION
Basal CKs are intermediate filaments present in the
myoepithelial and basal epithelial cells of the mammary
gland (14) and are recognized by the monoclonal antibody
CK 5/6. Basal CKs have been described in many types of
cancer, including breast tumors (15); along with other CKs,
they have been studied in the breast since the 1980s, either
to characterize normal histology or to evaluate the prognosis
of cancer (16–19). However, interest in basal CKs increased
after a study by Perou et al. (20) identified a ‘‘basal-like’’
subgroup of breast carcinomas characterized by a more
aggressive phenotype and by the expression of genes that
are normally active in the basal/myoepithelial cells of the
breast (14). Since then, numerous studies have described
surrogate immunohistochemical markers for characterizing
molecular subgroups, including a marker recognized by the
antibody CK 5/6 (9,21–23). Nielsen et al. defined the basal-
like subtype as a combination of the TN phenotype and
positive CK 5/6 and/or EGFR expression. The use of this
gene expression signature as the gold standard for
identifying the basal-like subtype was associated with 76%
sensitivity and 100% specificity (22). The same criteria have
been extended to the identification of a basal-like profile in
DCIS cases (12,24). Livasy et al. (12) identified the basal-like
phenotype in 19 of 245 (8%) patients with pure DCIS;
furthermore, all of their TN cases exhibited CK 5/6 and/or
EGFR expression. Among our cases, not all of the TN lesions
were basal-like. Among the 236 DCIS samples that we
examined, 25 (10.6%) cases were classified as the TN
subtype, and only 18 of these (72% of the TN cases and
7.6% of all the DCIS cases) also exhibited the basal-like
phenotype. The remaining 7 TN DCIS cases were also
negative for both CK 5/6 and EGFR. Although Livasy et al.
(12) reported no basal-like phenotypes among their low-
grade DCIS cases, we noted three cases with TN profiles in
the low-grade group, all of which were associated with
invasive carcinoma and two of which exhibited a basal-like
phenotype. Bryan et al. (24) observed the TN phenotype in 4
of 66 (6%) cases of high-grade DCIS, all of which exhibited a
basal-like phenotype. In that study, the expression of basal
Table 2 - Results of a multivariate analysis of the
pathological characteristics associated with invasion in
ductal carcinoma in situ (DCIS).
DCIS Variable OR 95% CI Coefficient SE p-value
Total ER/PR-negative 4.67 1.87–11.70 1.54 0.47 0.0010
HER2-positive 0.39 0.17–0.93 20.93 0.44 0.0333
CK 5/6-positive 0.22 0.10–0.48 21.5 0.39 0.0001
Low-grade CK 5/6-positive 0.22 0.09–057 21.5 0.49 0.0019
High-grade Triple-positive 0.09 0.02–0.51 22.37 0.87 0.006
CK 5/6-positive 0.28 0.09–0.93 21.24 0.59 0.04
ER: estrogen receptor; PR: progesterone receptor; HER2: human
epidermal growth factor 2; CK 5/6: cytokeratin 5/6; OR: odds ratio; SE:
standard error.
Table 1 - Distributions of age and morphological variables among 236 cases of ductal carcinoma in situ (DCIS) classified
as group 1 (pure DCIS without invasive carcinoma) and group 2 (DCIS with invasive breast carcinoma, a.k.a. DCIS+IBC).
Variable Group 1 (pure DCIS) Group 2(DCIS+IBC) p-value OR (95% CI)
n 90 146
Patient’s age (mean¡SD) 58.45 58.53 NS –
Nuclear grade 1–2 63 (70%) 93/144 (64.6%) 0.47* 1.28
3 27 (30%) 51/144 (35.4%) (0.73–2.25)
ER/PR Positive 76 (84.4%) 104 (71.2%) 0.03* 0.45
Negative 14 (15.6%) 42 (28.8%) (0.23–0.89)
HER2 Negative (0/1+) 69 (76.7%) 119 (81.5%) 0.46* 1.34
Positive (3+) 21 (23.3%) 27 (18.5%) (0.70–2.55)
Molecular profile Luminal (A+B) 65 (72.2%) 98 (67.1%) 0.01* –
TP 11 (12.2%) 6 (4.1%)
HER2 10 (11.1%) 21 (14.4%)
TN 4 (4.4%) 21 (14.4%)
CK 5/6 Positive 26/85 (30.6%) 15/133 (11.3%) 0.0007* 0.29
Negative 59/85 (69.4%) 118/133 (88.7%) (0.14–0.58)
EGFR Positive 9/85 (10.6%) 16/116 (13.8%) 0.64* 1.35
Negative 76/85 (89.4%) 100/116 (86.2%) (0.57–3.22)
*Chi-square; IBC: invasive breast cancer; ER: estrogen receptor; PR: progesterone receptor; HER2: human epidermal growth factor 2; CK 5/6: cytokeratin 5/
6; EGFR: epidermal growth factor receptor (human epidermal growth factor 1); TP: triple-positive (ER/PR/HER2-positive); TN: triple-negative (ER/PR/HER2-
negative).
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CK was also observed among in a subset of the non-TN
lesions. CK 5/6 was expressed in 16 of their 66 (24%) high-
grade DCIS cases. Besides, we observed the TN phenotype
in 22 of our 78 (28.2%) high-grade DCIS cases. Among these
cases, 17 exhibited the basal-like phenotype (CK 5/6- and/
or EGFR-positive), and most of them (15 cases) were CK 5/
6-negative but EGFR-positive. Besides, CK 5/6 expression
was identified in 17 of our 78 (21.8%) high-grade DCIS
cases, most of which were non-TN. Different from the
conclusion of Bryan et al., our results suggest that CK 5/6
expression in DCIS cases is not correlated with basal-like
invasive carcinoma. In fact, the most striking feature of the
neoplastic epithelial DCIS cells examined here was their
expression of basal CK 5/6, which indicates a low
probability of invasive disease, in both the low-grade and
high-grade groups. In addition, our results support a
negative association between CK 5/6 expression and the
TN phenotype; the latter was associated with more invasive
cases and higher-grade tumors. Interestingly, Steinman et al.
(25) observed a discordance between the CK marker
expression and ER/PR/EGFR status in cases of high-grade
DCIS and DCIS associated with invasive carcinoma (25).
The authors considered the hypotheses that pure DCIS
lesions correspond to earlier lesions than DCIS/IC that lack
some of the genetic changes necessary for progression to
IBC or that some pure DCIS cases are genetically pro-
grammed to not progress to IBC. Among our cases, both
invasive and in situ components of the same lesion
presented the same morphological and immunohistochem-
ical profile (data not shown). Based on this finding, it is
possible that basal CKs (identified by CK 5/6 staining) play
different roles in in situ neoplasms and invasive carcinomas,
particularly those of the basal-like TN subtype.
Zhou et al. (26) compared the risk of local recurrence/
invasive cancer between basal-like DCIS cases and DCIS
cases belonging to the other molecular subgroups (26).
Although basal-like DCIS was associated with a worse
prognosis, this difference was not significant. In the same
study, the TN phenotype and nuclear grade showed weak
power for stratifying the cases according to prognosis.
However, the authors did not explore the influence of basal
CK expression, which might partly explain their results.
Our findings suggest a possible utility of basal CK 5/6 for
selecting patients with low-grade DCIS who can be spared
radiation treatment without increasing the risk of invasive
disease. Radiation therapy following lumpectomy signifi-
cantly reduces the risk of local recurrence; however, there
are ongoing efforts to identify the subset of patients with
low-risk DCIS who may safely forgo radiation. Such a
finding would alter the paradigm of the necessity of
radiation treatment in all cases (27–31).
Another source of debate concerns the appropriate
indications for sentinel lymph node biopsy in patients with
pure DCIS (32–34). Most studies agree that sentinel lymph
node biopsy should be considered only in cases of DCIS
with a risk of invasive disease (32). The challenge is to
identify this subset of patients after a biopsy results in a
DCIS diagnosis. The features generally considered to
indicate lymph node biopsy are extensive DCIS, areas of
suspected microinvasion, irregular mass lesions and
planned mastectomy (34,35). Immunohistochemical mar-
kers have been correlated with the risk of recurrence, but
there has been minimal research analyzing these markers as
Table 3 - Pathological characteristics of the high-grade ductal carcinoma in situ (DCIS) cases (78 cases) according to the
presence or absence of associated invasive carcinoma (invasive breast carcinoma).
Variable Group 1 (pure DCIS) Group 2 (DCIS+IBC) Total p-value OR (95% CI)
n 27 51 78
ER/PR Positive 14 (51.8%) 15 (29.4%) 29 0.05 0.38 (0.14–1.01)
Negative 13 (48.2%) 36 (70.6%) 49
HER2 Positive (3+) 18 (66.7%) 20 (39.2%) 38 0.02 0.32 (0.12–0.86)
Negative (0/1+) 9 (33.3%) 31 (60.8%) 40
Molecular profile Luminal (A+B) 5 (27.8%) 13 (25.5%) 18 0.003 –
Triple-positive 9 (33.3%) 2 (3.9%) 11
HER2 9 (33.3%) 18 (35.3%) 27
Triple-negative 4 (14.8%) 18 (35.3%) 22
CK 5/6 Positive 9/26 (34.6%) 8/47 (17%) 17 0.09 0.38 (0.13–1.17)
Negative 17/26 (65.4%) 39/47 (83%) 56
EGFR Positive 7 (25.9%) 13/40 (32.5%) 20 0.56 1.37 (0.46–4.07)
Negative 20 (74.1%) 27/40 (67.5%) 47
ER: estrogen receptor; PR: progesterone receptor; HER2: human epidermal growth factor 2; CK 5/6: cytokeratin 5/6; EGFR: epidermal growth factor
receptor (human epidermal growth factor 1).
Figure 1 - High-grade ductal carcinoma in situ (DCIS) (A) showing
positive membranous-cytoplasmic immunostaining for basal
cytokeratin (CK 5/6) (B); and low-grade DCIS (C) showing positive
membranous-cytoplasmic immunostaining for CK 5/6 (D) (origi-
nal magnification 100X).
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indicators of the risk of invasion. In this regard, our results
yield some interesting data. We could speculate that the
low-grade DCIS patients who would benefit the most from
conservative approaches might be those with positive CK 5/
6 expression, regardless of their molecular profile, because
this group did not demonstrate evidence of an influence of
hormonal status or HER2 expression. In contrast, high-
grade DCIS cases with a triple-positive phenotype (ER/PR/
HER2) and positive CK 5/6 expression might correspond to
less aggressive lesions. Our study had some limitations due
to its retrospective design. Additional investigations to
confirm and extend our findings would be valuable.
Another interesting issue is the role of HER2 overexpression
in DCIS. In this study, we observed that the proportions of
both HER2 positivity and HER2-enriched profiles were similar
between the pure DCIS and DCIS/IC cases. However, triple-
positive profile was predominant in the high-grade pure DCIS
group compared with the high-grade DCIS/IBC group (33.3%
vs. 3.9%, p= 0.003). This difference remained after a multi-
variate analysis, with an OR of 0.09 (CI 0.02-0.51) for predicting
invasion. A comparison of our results with the published data
would be difficult because HER2 overexpression is mainly
found in high-grade DCIS cases. In addition, HER2 over-
expression is generally analyzed independently of ER/PR co-
expression, except when the focus is determining its predictive
value for therapeutic response (36). However, we found
support for our results in a study by Rakovitch et al. (37), who
identified a combination of HER2 overexpression and Ki-67
expression as an independent profile predictor of noninvasive
recurrence following breast-conserving therapy. This result is
interesting because it does not deny the more aggressive
nature and greater risk of recurrence associated with HER2-
positive DCIS, but it shows that recurrence is more common in
in situ disease. Han et al. (38) reported high rates (40% and
38%) of local recurrence among DCIS cases with either co-
expression of ER/PR or HER2 enrichment, respectively.
However, although those authors observed a trend toward
higher rates of invasive recurrence in HER-positive cases, they
did not analyze cases of invasive and in situ recurrence
separately (38). In contrast, Harada et al. (39) identified the
ER/PR/HER2-positive phenotype as exhibiting the highest
risk of progression to invasive disease. The influence of the co-
expression of ER/PR in HER2-positive neoplasms is far from
clear.
At this point, the challenge is to investigate which basal
CKs, such as those recognized by CK 5/6, can be combined
with other biomarkers to define a low-risk DCIS subgroup.
Larger studies involving systematic evaluations of patholo-
gical and molecular parameters, longer follow-ups, adjust-
ments for treatment effects and validation are needed to
improve risk stratification and treatment planning for
women with DCIS.
According to our results, the immunoexpression of basal
CK 5/6 in both high-grade and low-grade DCIS lesions
indicates a lower risk of invasive carcinoma.
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